D.A. Davidson & CO. Has $937,000 Holdings in Global Medical REIT Inc. (GMRE)

D.A. Davidson & CO. raised its holdings in Global Medical REIT Inc. (NYSE:GMRE) by 36.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 104,430 shares of the company’s stock after acquiring an additional 27,667 shares during the quarter. D.A. Davidson & CO. owned about 0.48% of Global Medical REIT worth $937,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. UBS Group AG lifted its stake in Global Medical REIT by 14.2% in the first quarter. UBS Group AG now owns 11,847 shares of the company’s stock valued at $108,000 after acquiring an additional 1,477 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Global Medical REIT in the third quarter worth $115,000. Wedbush Securities Inc. lifted its stake in shares of Global Medical REIT by 5.8% in the second quarter. Wedbush Securities Inc. now owns 15,334 shares of the company’s stock worth $137,000 after buying an additional 834 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Global Medical REIT in the third quarter worth $154,000. Finally, Rhumbline Advisers lifted its stake in shares of Global Medical REIT by 47.6% in the second quarter. Rhumbline Advisers now owns 17,699 shares of the company’s stock worth $158,000 after buying an additional 5,710 shares during the last quarter. Hedge funds and other institutional investors own 35.93% of the company’s stock.

Shares of Global Medical REIT Inc. (NYSE GMRE) traded up $0.16 during trading on Monday, hitting $9.75. 71,300 shares of the stock were exchanged, compared to its average volume of 131,236. The company has a debt-to-equity ratio of 0.72, a current ratio of 0.22 and a quick ratio of 0.22. Global Medical REIT Inc. has a twelve month low of $7.12 and a twelve month high of $10.25. The firm has a market capitalization of $210.90, a PE ratio of 25.00, a price-to-earnings-growth ratio of 3.10 and a beta of -49.42.

A number of analysts have recently weighed in on the stock. B. Riley restated a “buy” rating and issued a $10.50 price objective on shares of Global Medical REIT in a research note on Friday, November 10th. DA Davidson cut shares of Global Medical REIT from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $11.00 to $10.00 in a research note on Tuesday, August 22nd. Zacks Investment Research upgraded shares of Global Medical REIT from a “sell” rating to a “hold” rating and set a $10.00 price objective for the company in a research note on Tuesday, November 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $12.00 price objective on shares of Global Medical REIT in a research note on Friday, September 1st. Finally, FBR & Co restated a “buy” rating and issued a $10.50 price objective (up from $10.00) on shares of Global Medical REIT in a research note on Monday, September 18th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $10.60.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/11/27/d-a-davidson-co-has-937000-holdings-in-global-medical-reit-inc-gmre.html.

Global Medical REIT Company Profile

Institutional Ownership by Quarter for Global Medical REIT (NYSE:GMRE)

Receive News & Ratings for Global Medical REIT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Medical REIT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply